RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7
Strategic Advancements and Market Opportunities Propel Verastem's Buy Rating
Optimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem's Avutometinib and Defactinib
Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15
Verastem Price Target Maintained With a $13.00/Share by RBC Capital
Verastem Analyst Ratings
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7
Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15
Truist Remains Bullish on Verastem, Says Weakness in Shares 'an Overreaction'
Verastem Stock: Buy Rating Amid Market Overreaction and Promising Commercial Potential
Verastem Analyst Ratings
Guggenheim Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $13
Verastem Initiated With a Buy at Guggenheim
Outperform Rating and $7 Target for Verastem Amidst LGSOC Treatment Potential and Stock Valuation Opportunity
Verastem Analyst Ratings
Buy Rating Affirmed for Verastem: Financial Stability and Promising Drug Pipeline Fuel Optimism
Verastem Analyst Ratings
RBC Adjusts Price Target on Verastem to $13 From $16, Maintains Outperform Rating